Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1

Conditions

Breast Neoplasms 545Lymphoma 444Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Lymphoma, Large B-Cell, Diffuse 347Leukemia 344Multiple Myeloma 335Lymphoma, Non-Hodgkin 316Leukemia, Myeloid, Acute 288Leukemia, Lymphocytic, Chronic, B-Cell 285Lymphoma, Follicular 240Burkitt Lymphoma 217Myelodysplastic Syndromes 209Lymphoma, Mantle-Cell 201Hodgkin Disease 193Recurrence 151Lymphoma, B-Cell, Marginal Zone 142Melanoma 134Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 94Triple Negative Breast Neoplasms 93Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

eribulin 3Vinorelbine 2Paclitaxel 2Epirubicin 2Doxorubicin 2Cyclophosphamide 2trastuzumab deruxtecan 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1camrelizumab 1anlotinib 1Taxes 1Precision Medicine 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HER2-negative Breast Cancer × Cyclophosphamide × Clear all
NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

National University Hospital, Singapore

Phase 1/2 Active not recruiting
66 enrolled
BreastOther solid neoplasm

HER2-negative Breast Cancer

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡